Enfuvirtide: from basic investigations to current clinical use

Bibliography

• De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002;22:531-65
   PubMed Web of Science ®Google Scholar
• Fuzeon [Package insert]. Trimeris, Inc., and Roche Laboratories, Inc., Durham, NC and Nutley, NJ; 2003
   Google Scholar
• Kilby JM, Eron J. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003;348:2228-38
   PubMed Web of Science ®Google Scholar
• Gallaber W, Ball J, Garry J, A general model of the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989;5:431-40
   PubMedGoogle Scholar
• Delwart E, Mosialos G, Gilmore T. Retroviral envelope glycoproteins contain a ‘leucine zipper’-like repeat. AIDS Res Hum Retroviruses 1989;6:703-6
   Web of Science ®Google Scholar
• Reeves JD, Gallo SA, Ahmad N, Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-54
   PubMed Web of Science ®Google Scholar
• Cooley SA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol 2003;26:121-32
   PubMed Web of Science ®Google Scholar
• Lu M, Blacklow S, Kim P. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-82
   PubMedGoogle Scholar
• Carr C, Kim PS. A spring-loaded mechanism for the conformational change on influenza hemaglutinin. Cell 1993;73:823-32
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Radoshitzky SR, Choe H, Severe acute respiratory syndrome coronavirus entry as a target for antiviral therapies. Antivir Ther 2007;12:639-50
   PubMedGoogle Scholar
• Dietrich U. HIV-1 entry inhibitors. AIDS Rev 2001;3:89-97
   Google Scholar
• Martin-Carbonero L. Discontinuation of the clinical development of the fusion inhibitor T-1249. AIDS Rev 2004;6:61
   PubMedGoogle Scholar
• Ketas TJ, Klasse PJ, Spenlehauer C, Entry inhibitors SCH-C, RANTES and T-20 block HIV type I replication in multiple cell types. AIDS Res Hum Retroviruses 2003;19:177-86
   PubMed Web of Science ®Google Scholar
• Derdeyn CA, Decker JM, Sfakianos JN, Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74:8358-67
   PubMed Web of Science ®Google Scholar
• Melby T, Sista P, DeMasi R, Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22:375-85
   PubMed Web of Science ®Google Scholar
• Whitcomb J, Huang W, Fransen S, Analysis of baseline enfuvirtide (T-20) susceptibility and co-receptor tropism in two phase III study populations [abstract 557]. Presented at the 10th Conference on Retrovirus and Opportunistic Infections; 10 – 14 February 2003; Boston, MA, USA
   Google Scholar
• Villahermosa ML, Perez-Alvarez L, Carmona R, Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of non-B subtypes and recombinants. AIDS 2003;17:1083-6
   PubMed Web of Science ®Google Scholar
• Holguin A, Faudon JL, Labernardiere JL, Susceptibility of HIV-1 non-B subtypes and recombinant variances to enfuvirtide. J Clin Virol 2007;38:176-80
   PubMed Web of Science ®Google Scholar
• Cilliers T, Patience T, Pillay C, Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004;20:477-82
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Application number 21-481. Microbiological review(s). Available from: http://www.fda.gov/cder/foi/nda/2003/21481_Fuzeon_Microbr.pdf [Last accessed 31 October 2003]
   Google Scholar
• Kilby JM, Hopkins S, Venetta TM, Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-7
   PubMed Web of Science ®Google Scholar
• Roman R, Gonzalez D, Lambert C, Uncommon mutations at residue positions critical for enfuvirtide T-20 resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003;33:134-9
   PubMedGoogle Scholar
• Rimsky L, Shugars D, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-93
   PubMed Web of Science ®Google Scholar
• Poveda E, Rodes B, Lebel-Binay S, Dynamics of enfuvirtide resistance in HIV-infected patients during and after enfuvirtide salvage therapy. J Clin Virol 2005;34:295-301
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Henry K, O'Hearn M, ; for the TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for the drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, ; for the TORO 2 study group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2186-95
   PubMed Web of Science ®Google Scholar
• Johnson V, Brun-Vezinet F, Clotet B, Update of drug resistance mutations in HIV-1. Top HIV Med 2008;16:138-45
   PubMedGoogle Scholar
• Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-40
   PubMed Web of Science ®Google Scholar
• Labrosse B, Morand-Joubert L, Goubard A, Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006;80:8807-19
   PubMed Web of Science ®Google Scholar
• Lu J, Sista P, Giguel F, Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004;78:4628-37
   PubMed Web of Science ®Google Scholar
• Menzo S, Casragna A, Monachetti A, Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment. New Microbiol 2004;27:51-61
   PubMedGoogle Scholar
• Deeks S, Lu J, Hoh R, Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007;195:387-91
   PubMed Web of Science ®Google Scholar
• Su C, Melby R, DeMasi P, Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J Clin Virol 2006;36:249-57
   PubMed Web of Science ®Google Scholar
• Xu L, Pozniak A, Wildfire SA, Emergence and evolution of enfuvirtide resistance following long-term therapy involves hepted repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-19
   PubMed Web of Science ®Google Scholar
• Ray N, Blackburn LA, Doms RW. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Clin Virol 2009;83:2989-95
   Google Scholar
• Kilby JM, Lalezari JP, Eron JJ, The safety, plasma pharmacokinetics and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18:685-93
   PubMed Web of Science ®Google Scholar
• Bellibas SE, Siddique Z, Dorr A, ; for the T20310/NV16056 Study Group. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004;23:1137-41
   PubMed Web of Science ®Google Scholar
• Tebas P, Bellos N, Lucasti C, Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr 2008;47:342-5
   PubMed Web of Science ®Google Scholar
• Raffi F, Battegay M, Rusconi S, Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21:1977-80
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Eron JJ, Carlson M, A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-8
   PubMed Web of Science ®Google Scholar
• Lalezari JP, DeJesus E, Northfelt G, A controlled phase II trial evaluating assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir ritonavir and efavirenz in non nucleoside reverse transcriptase inhibitor-naive HIV-infected patients. Antivir Ther 2003;8:279-87
   PubMed Web of Science ®Google Scholar
• Nelson M, Arasteh K, Clotet B, Durable efficacy over 48 weeks in heavily treatment experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-12
   PubMed Web of Science ®Google Scholar
• Montaner J, Guimaraes D, Chung J, Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials 2005;6:281-90
   PubMed Web of Science ®Google Scholar
• Reynes J, Arasteh K, Clotet B, TORO: ninety-six week virologic and immunologic response and safety evaluation on enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007;21:533-43
   PubMed Web of Science ®Google Scholar
• Hicks C, Cahn P, Cooper DA, Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir RESIST studies: an analysis of combined data from two randomized open-label trials. Lancet 2006;368:466-75
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet 2007;369:1169-78
   PubMed Web of Science ®Google Scholar
• Clotet B, Capetti A, Soto-Ramirez LE, A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. J Antimicrob Chemother 2008;62:1374-8
   PubMedGoogle Scholar
• Kaufmann EL, Weber R, Fux CA, ; Swiss HIV Cohort Study. Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clin Trials 2009;10:207-14
   PubMedGoogle Scholar
• De Castro N, Braun J, Charreau I, Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1 infected patients: a randomized open-label trial. Clin Infect Dis 2009;49:1259-67
   PubMed Web of Science ®Google Scholar
• Towner W, Klein D, Kerrigan HL, Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 infected patients well controlled on an enfuvirtide based regimen: 24 weeks results of the CHEER study. J Acquir Immune Defic Syndr 2009;51:367-73
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008;22:1224-6
   PubMed Web of Science ®Google Scholar
• Viard JP, Fagard C, Chaix ML, Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunosuppressed patients. AIDS 2009;23:1383-88
   PubMedGoogle Scholar
• Joly V, Fagard C, Descamps D, Intensification of HAART through the addition of enfuvirtide in naive HIV-infected patients with severe immunosuppression does not improve immunological response: results of a prospective randomized multicenter trial (APOLLO-ANRS 130) [abstract 282]. Presented at the 17th Conference on Retrovirus and Opportunistic Infections; 16 – 19 February 2010; San Francisco, CA, USA
   Google Scholar
• Haberl A, Linde R, Reitter A, Use of enfuvirtide in HIV+ pregnant women [abstract 627b]. Presented at the 15th Conference on Retrovirus and Opportunistic Infections; 3 – 6 February 2008; Boston, MA, USA
   Google Scholar
• Teicher E, Abbara C, Duclos-Vallee JC, Enfuvirtide: a safe and effective antiretroviral agent of human immunodeficiency virus-infected patients shortly after liver transplantation. Liver Transplant 2009;15:1336-42
   PubMedGoogle Scholar
• Ball RA, Kinchelow T, ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 2003;49:826-31
   PubMed Web of Science ®Google Scholar
• Maggi P, Ladisa N, Cinori E, Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004;53:678-81
   PubMed Web of Science ®Google Scholar
• Loufty MR, Harris M, Raboud JM, A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration. HIV Med 2007;8:427-32
   PubMedGoogle Scholar
• Harris M, Joy R, Larsen G, Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006;20:719-23
   PubMed Web of Science ®Google Scholar
• Trottier B, Walmsley S, Reynes J, Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV 1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413-21
   PubMed Web of Science ®Google Scholar
• Kousignian I, Launay O, Mayaud C, Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? J Antimicrob Chemother 2010;65:138-44
   PubMedGoogle Scholar
• Cohen CJ, Clumeck N, Molina JM, Health-related quality of life with enfuvirtide in combination with an optimized background regimen. J Acquir Immune Defic Syndr 2004;37:1140-6
   PubMed Web of Science ®Google Scholar
• Tremblay CL, Kollmann C, Giguel C, Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000;25:99-102
   PubMed Web of Science ®Google Scholar
• Melby TE, Despirito M, Demasi RA, Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007;21:2537-9
   PubMed Web of Science ®Google Scholar